Literature DB >> 16184405

Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician's Health Study.

Sarah A Rosner1, Paul M Ridker, Robert Y L Zee, Nancy R Cook.   

Abstract

Inflammation is known to be a major component of atherosclerosis, and cigarette smoking is known to induce a systemic inflammatory response. We therefore, investigated possible gene-environment interactions between various inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction (MI) in the Physician's Health Study (PHS), a cohort of initially healthy middle-aged men. We used a nested case-control design consisting of 522 MI cases and 2,089 controls derived from PHS. Eleven inflammatory polymorphisms were studied using logistic regression analysis: eotaxin (ala23thr), intercellular adhesion molecule 1 (gly241arg), interleukin-4 (582C>T), interleukin-4 receptor (ile75val, gln576arg), interleukin-6 (-174G>C), interleukin-10 (-571C>A), P-selectin (val640leu, thr756pro, ser330asn), and vascular cell adhesion molecule 1 (-1594T>C). Interactions of smoking with all the three modes of inheritance (additive, dominant, recessive) were tested. Statistically significant (P<0.05) interaction terms were found for interleukin-4 receptor (ile75val), with odds ratios of 0.52 (95%CI:0.29-0.95) for Ile-Val and 0.34 (95%CI:0.14-0.83) for Val-Val, compared to the wildtype Ile-Ile; for interleukin-6 (-174G>C) with odds ratios of 2.16 (1.14-4.09) for GC and 0.81 (0.31-2.12) for CC, compared to the wildtype GG; and for P-selectin (ser330asn) with odds ratios of 0.48 (0.24-0.95) for Ser-Asn and 1.08 (0.29-3.93) for Asn-Asn, compared to the wildtype Ser-Ser, with these effects occurring only among the smokers. These data raise the possibility of interaction between the smoking status and certain inflammatory polymorphisms on the risk of MI in men. However, these results should be interpreted with caution due to the potential for false positive results that can arise from analyses with multiple comparisons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16184405     DOI: 10.1007/s00439-005-0052-6

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  31 in total

1.  Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease.

Authors:  A M Carter; K Anagnostopoulou; M W Mansfield; P J Grant
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

2.  Soluble P-selectin and the risk of future cardiovascular events.

Authors:  P M Ridker; J E Buring; N Rifai
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

3.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.

Authors:  S E Humphries; L A Luong; M S Ogg; E Hawe; G J Miller
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

4.  Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils.

Authors:  H Niiro; T Otsuka; K Izuhara; K Yamaoka; K Ohshima; T Tanabe; S Hara; Y Nemoto; Y Tanaka; H Nakashima; Y Niho
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

5.  A novel polymorphism in the 5' promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels.

Authors:  H Hackstein; M Hecker; S Kruse; A Bohnert; C Ober; K A Deichmann; G Bein
Journal:  Immunogenetics       Date:  2001 May-Jun       Impact factor: 2.846

6.  Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Témoin de l'Infarctus du Myocarde.

Authors:  J L Georges; V Loukaci; O Poirier; A Evans; G Luc; D Arveiler; J B Ruidavets; F Cambien; L Tiret
Journal:  J Mol Med (Berl)       Date:  2001-06       Impact factor: 4.599

7.  Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.

Authors:  S J Hwang; C M Ballantyne; A R Sharrett; L C Smith; C E Davis; A M Gotto; E Boerwinkle
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

8.  Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Stephan Fichtlscherer; Eric Boersma; Maarten L Simoons; Andreas M Zeiher
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

9.  Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).

Authors:  Federica Basso; Gordon D O Lowe; Ann Rumley; Alex D McMahon; Steve E Humphries
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

10.  The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.

Authors:  Markus Nauck; Bernhard R Winkelmann; Michael M Hoffmann; Bernhard O Böhm; Heinrich Wieland; Winfried März
Journal:  J Mol Med (Berl)       Date:  2002-06-21       Impact factor: 4.599

View more
  15 in total

1.  Association between three single nucleotide polymorphisms in eotaxin (CCL 11) gene, hexanucleotide repetition upstream, severity and course of coronary atherosclerosis.

Authors:  J Máchal; A Vašků; V Kincl; M Hlavna; V Bartáková; M Jurajda; J Meluzín
Journal:  J Appl Genet       Date:  2012-07-07       Impact factor: 3.240

2.  Risk of Acute Stroke After Hospitalization for Sepsis: A Case-Crossover Study.

Authors:  Amelia K Boehme; Purnima Ranawat; Jorge Luna; Hooman Kamel; Mitchell S V Elkind
Journal:  Stroke       Date:  2017-02-14       Impact factor: 7.914

Review 3.  Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis.

Authors:  Haifeng Hou; Chenglin Wang; Fengjing Sun; Linlin Zhao; Aishe Dun; Zheng Sun
Journal:  Inflamm Res       Date:  2015-07-15       Impact factor: 4.575

4.  SELP genetic polymorphisms may contribute to the pathogenesis of coronary heart disease and myocardial infarction: a meta-analysis.

Authors:  Dong-Hui Zhou; Yong Wang; Wei-Na Hu; Li-Jie Wang; Qi Wang; Miao Chi; Yuan-Zhe Jin
Journal:  Mol Biol Rep       Date:  2014-02-07       Impact factor: 2.316

5.  Correlations of SELE and SELP genetic polymorphisms with myocardial infarction risk: a meta-analysis and meta-regression.

Authors:  Yu-Juan Zhao; Xia Yang; Li Ren; An-Sheng Cai; Yan-Fen Zhang
Journal:  Mol Biol Rep       Date:  2014-03-18       Impact factor: 2.316

6.  IL-6 gene polymorphisms and CAD risk: a meta-analysis.

Authors:  Yuan Yang; Fan Zhang; Laura Skrip; Han Lei; Yang Wang; Dayi Hu; Rongjing Ding
Journal:  Mol Biol Rep       Date:  2012-12-16       Impact factor: 2.316

7.  Association between three interleukin-10 gene polymorphisms and coronary artery disease risk: a meta-analysis.

Authors:  Bing-Jian Wang; Jie Liu; Jin Geng; Qing Zhang; Ting-Ting Hu; Biao Xu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Interaction between air pollution exposure and genes in relation to levels of inflammatory markers and risk of myocardial infarction.

Authors:  Sviatlana Panasevich; Karin Leander; Petter Ljungman; Tom Bellander; Ulf de Faire; Göran Pershagen; Fredrik Nyberg
Journal:  BMJ Open       Date:  2013-09-19       Impact factor: 2.692

9.  Chronic medical conditions and risk of sepsis.

Authors:  Henry E Wang; Nathan I Shapiro; Russell Griffin; Monika M Safford; Suzanne Judd; George Howard
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Heterogeneous effect of two selectin gene polymorphisms on coronary artery disease risk: a meta-analysis.

Authors:  Zhijun Wu; Yuqing Lou; Lin Lu; Yan Liu; Qiujing Chen; Xin Chen; Wei Jin
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.